KR20230024904A - Sars-cov-2에 대한 강력한 중화 항체, 그의 생성 및 용도 - Google Patents

Sars-cov-2에 대한 강력한 중화 항체, 그의 생성 및 용도 Download PDF

Info

Publication number
KR20230024904A
KR20230024904A KR1020227044068A KR20227044068A KR20230024904A KR 20230024904 A KR20230024904 A KR 20230024904A KR 1020227044068 A KR1020227044068 A KR 1020227044068A KR 20227044068 A KR20227044068 A KR 20227044068A KR 20230024904 A KR20230024904 A KR 20230024904A
Authority
KR
South Korea
Prior art keywords
seq
identical polypeptide
cdr2
cdr1
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227044068A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 디. 호
야오싱 황
리홍 리우
마노즈 에스. 나이르
펑페이 왕
지엔 위
양 루오
Original Assignee
더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 filed Critical 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕
Publication of KR20230024904A publication Critical patent/KR20230024904A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C07K16/1045—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227044068A 2020-05-20 2021-05-20 Sars-cov-2에 대한 강력한 중화 항체, 그의 생성 및 용도 Pending KR20230024904A (ko)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202063027935P 2020-05-20 2020-05-20
US63/027,935 2020-05-20
US202063032518P 2020-05-29 2020-05-29
US63/032,518 2020-05-29
US202063039977P 2020-06-16 2020-06-16
US63/039,977 2020-06-16
US202063060116P 2020-08-02 2020-08-02
US63/060,116 2020-08-02
US202063063106P 2020-08-07 2020-08-07
US63/063,106 2020-08-07
US202063117908P 2020-11-24 2020-11-24
US63/117,908 2020-11-24
US202063123767P 2020-12-10 2020-12-10
US63/123,767 2020-12-10
US202163165729P 2021-03-24 2021-03-24
US63/165,729 2021-03-24
PCT/US2021/033512 WO2021236997A2 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof

Publications (1)

Publication Number Publication Date
KR20230024904A true KR20230024904A (ko) 2023-02-21

Family

ID=78707603

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227044068A Pending KR20230024904A (ko) 2020-05-20 2021-05-20 Sars-cov-2에 대한 강력한 중화 항체, 그의 생성 및 용도

Country Status (13)

Country Link
US (3) US20230203134A1 (https=)
EP (1) EP4153625A4 (https=)
JP (1) JP2023526469A (https=)
KR (1) KR20230024904A (https=)
AU (1) AU2021277373A1 (https=)
BR (1) BR112022023467A2 (https=)
CA (1) CA3184184A1 (https=)
CL (1) CL2022003215A1 (https=)
CO (1) CO2022018192A2 (https=)
IL (1) IL298263A (https=)
MX (1) MX2022014420A (https=)
PH (1) PH12022500025A1 (https=)
WO (4) WO2021236997A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240182T1 (hr) 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
EP4153625A4 (en) * 2020-05-20 2024-09-25 The Trustees Of Columbia University In The City Of New York STRONG NEUTRALISING ANTIBODIES AGAINST SARS-COV-2, THEIR PRODUCTION AND USE
WO2024089277A2 (en) * 2022-10-27 2024-05-02 Oxford University Innovation Limited Antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778283A2 (en) * 2004-06-30 2007-05-02 ID Biomedical Corporation of Quebec Vaccine compositions for treating coronavirus infection
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
CA2662350A1 (en) * 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2242768A4 (en) * 2008-01-17 2012-03-14 Humabs Llc CROSS-NEUTRALIZATION OF HUMAN MONOCLONAL ANTIBODIES AGAINST SARS-COV AND METHODS FOR THEIR APPLICATION
CN108610416B (zh) * 2008-10-13 2022-01-14 生物医学研究所 登革热病毒中和抗体及其用途
CA2742969A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
CA2932405A1 (en) * 2013-12-02 2015-06-11 Aaron Diamond Aids Research Center Improved hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture
WO2016138160A1 (en) * 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
WO2016187220A2 (en) * 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN113056483B (zh) * 2018-07-09 2025-08-01 戊瑞治疗有限公司 结合到ilt4的抗体
EP4153625A4 (en) * 2020-05-20 2024-09-25 The Trustees Of Columbia University In The City Of New York STRONG NEUTRALISING ANTIBODIES AGAINST SARS-COV-2, THEIR PRODUCTION AND USE

Also Published As

Publication number Publication date
US20230203134A1 (en) 2023-06-29
AU2021277373A1 (en) 2023-01-05
WO2021236998A3 (en) 2021-12-16
CL2022003215A1 (es) 2023-07-07
CA3184184A1 (en) 2021-11-25
US20240002476A1 (en) 2024-01-04
BR112022023467A2 (pt) 2023-03-28
WO2021236995A3 (en) 2022-09-15
WO2021236998A2 (en) 2021-11-25
JP2023526469A (ja) 2023-06-21
EP4153625A4 (en) 2024-09-25
WO2021236997A3 (en) 2022-09-29
WO2021236996A3 (en) 2022-11-17
MX2022014420A (es) 2023-03-21
IL298263A (en) 2023-01-01
WO2021236996A2 (en) 2021-11-25
WO2021236997A2 (en) 2021-11-25
CO2022018192A2 (es) 2023-03-17
WO2021236995A2 (en) 2021-11-25
PH12022500025A1 (en) 2024-03-25
EP4153625A2 (en) 2023-03-29
WO2021236998A9 (en) 2022-03-31
US20230203138A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
JP7684379B2 (ja) 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片
CN113874394B (zh) 抗体
KR20230024904A (ko) Sars-cov-2에 대한 강력한 중화 항체, 그의 생성 및 용도
EP4230650B1 (en) Antibodies capable of binding to the spike protein of coronavirus sars-cov-2
US20250154231A1 (en) Antibodies capable of binding to the spike protein of cononavirus sars-cov-2
US20240101645A1 (en) Monoclonal antibodies against coronaviruses and uses thereof
EP4206224A1 (en) Human antibody or antigen-binding fragment thereof against coronavirus spike protein
EP4585687A1 (en) Human antibody against coronavirus variants or antigen-binding fragment thereof
WO2020233715A1 (zh) 抗乙肝病毒抗体及其用途
US12523656B2 (en) Antibodies against SARS-CoV-2 spike protein
US20230382979A1 (en) Anti-sars-cov-2 antigen antibodies and related compositions and methods
CN114751988A (zh) 中和冠状病毒的多特异性抗体
CN115087667A (zh) 特异性结合SARS-CoV-2的抗原结合蛋白
WO2022060900A1 (en) Shark-derived binding molecules for sars-cov-2 coronavirus and uses thereof
CN116829177A (zh) 抗SARS-CoV-2的有效中和抗体及其生成和用途
EP4108256A1 (en) Anti-ospa antibodies and methods of use
WO2023025813A1 (en) Neutralizing antibodies directed to sars-cov-2 spike protein
WO2023077429A1 (en) TRIMERIC ANTIBODIES AGAINST SARS-CoV-2 SPIKE PROTEIN
CN115028714A (zh) 一种检测冠状病毒的抗体及其应用
WO2025083216A1 (en) Antibodies specific for the spike protein of sars cov-2 coronavirus

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000